PDZ-binding kinase promotes ovarian cancer cell proliferation and invasion via CCNB1 regulation.

IF 2.1 4区 医学 Q4 ONCOLOGY
Translational cancer research Pub Date : 2026-08-31 Epub Date: 2026-08-27 DOI:10.21037/tcr-2026-1337
Guzhanuer Awuti, Jiapo Wang, Yun Lu, Haonan Jiang, Xiaoqing Guo
{"title":"PDZ-binding kinase promotes ovarian cancer cell proliferation and invasion via <i>CCNB1</i> regulation.","authors":"Guzhanuer Awuti, Jiapo Wang, Yun Lu, Haonan Jiang, Xiaoqing Guo","doi":"10.21037/tcr-2026-1337","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer is one of the most lethal gynecological malignancies, characterized by late diagnosis, frequent recurrence, and high mortality. PDZ-binding kinase (PBK), a serine/threonine kinase of the mitogen-activated protein kinase kinase (MAPKK) family, has been implicated in the tumorigenesis of multiple cancers, yet its role in ovarian cancer remains incompletely characterized. This study aimed to investigate the effect of PBK on the proliferation and invasion of ovarian cancer cells.</p><p><strong>Methods: </strong>The expression of <i>PBK</i> and cyclin B1 (<i>CCNB1</i>) in normal ovarian tissues and ovarian cancer tissues was analyzed using online databases including Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Clinical Proteomic Tumor Analysis Consortium (CPTAC), and Kaplan-Meier Plotter. Clinical tissue specimens were collected to detect the expression of PBK and <i>CCNB1</i> by immunohistochemistry. Quantitative real-time polymerase chain reaction (PCR) was performed to detect PBK messenger RNA (mRNA) expression levels in clinical specimens and cell lines. Western blot was used to detect PBK protein expression in ovarian cancer cell lines. ES2 and A2780 cells with higher PBK expression were selected to construct <i>PBK</i> knockdown cell lines using lentiviral interference vectors. Cell Counting Kit-8 (CCK-8) assay, colony formation assay, and 5-ethynyl-2'-deoxyuridine (EdU) assay were performed to explore the effect of <i>PBK</i> knockdown on cell proliferation. Transwell assay was used to investigate the effect on cell invasion. The Cancer Genome Atlas (TCGA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were utilized to analyze <i>PBK</i>-related pathways and predict <i>CCNB1</i> as the gene most closely related to <i>PBK</i>.</p><p><strong>Results: </strong>PBK was significantly overexpressed in ovarian cancer tissues and cell lines compared with normal controls, and high <i>PBK</i> expression was associated with poor overall survival (OS) and progression-free survival (PFS). Knockdown of <i>PBK</i> expression inhibited the proliferation, colony formation, and invasion of ovarian cancer cells. Bioinformatics analysis revealed that <i>CCNB1</i> was significantly overexpressed in ovarian cancer and high <i>CCNB1</i> expression was associated with poor OS. <i>CCNB1</i> was also significantly highly expressed in ovarian cancer tissues as validated by immunohistochemistry and was associated with lymph node metastasis. <i>PBK</i> and <i>CCNB1</i> expression showed a significant positive correlation in TCGA ovarian cancer datasets. Knockdown of PBK inhibited CCNB1 expression in ovarian cancer cells.</p><p><strong>Conclusions: </strong>PBK promotes ovarian cancer cell proliferation and invasion. PBK knockdown leads to <i>CCNB1</i> downregulation. These findings suggest that <i>CCNB1</i> contributes to PBK-mediated oncogenic effects and identify the <i>PBK-CCNB1</i> axis as a potential therapeutic target for ovarian cancer treatment.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"15 8","pages":"571"},"PeriodicalIF":2.1000,"publicationDate":"2026-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13559573/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2026-1337","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/27 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ovarian cancer is one of the most lethal gynecological malignancies, characterized by late diagnosis, frequent recurrence, and high mortality. PDZ-binding kinase (PBK), a serine/threonine kinase of the mitogen-activated protein kinase kinase (MAPKK) family, has been implicated in the tumorigenesis of multiple cancers, yet its role in ovarian cancer remains incompletely characterized. This study aimed to investigate the effect of PBK on the proliferation and invasion of ovarian cancer cells.

Methods: The expression of PBK and cyclin B1 (CCNB1) in normal ovarian tissues and ovarian cancer tissues was analyzed using online databases including Gene Expression Profiling Interactive Analysis 2 (GEPIA2), Clinical Proteomic Tumor Analysis Consortium (CPTAC), and Kaplan-Meier Plotter. Clinical tissue specimens were collected to detect the expression of PBK and CCNB1 by immunohistochemistry. Quantitative real-time polymerase chain reaction (PCR) was performed to detect PBK messenger RNA (mRNA) expression levels in clinical specimens and cell lines. Western blot was used to detect PBK protein expression in ovarian cancer cell lines. ES2 and A2780 cells with higher PBK expression were selected to construct PBK knockdown cell lines using lentiviral interference vectors. Cell Counting Kit-8 (CCK-8) assay, colony formation assay, and 5-ethynyl-2'-deoxyuridine (EdU) assay were performed to explore the effect of PBK knockdown on cell proliferation. Transwell assay was used to investigate the effect on cell invasion. The Cancer Genome Atlas (TCGA) and Kyoto Encyclopedia of Genes and Genomes (KEGG) databases were utilized to analyze PBK-related pathways and predict CCNB1 as the gene most closely related to PBK.

Results: PBK was significantly overexpressed in ovarian cancer tissues and cell lines compared with normal controls, and high PBK expression was associated with poor overall survival (OS) and progression-free survival (PFS). Knockdown of PBK expression inhibited the proliferation, colony formation, and invasion of ovarian cancer cells. Bioinformatics analysis revealed that CCNB1 was significantly overexpressed in ovarian cancer and high CCNB1 expression was associated with poor OS. CCNB1 was also significantly highly expressed in ovarian cancer tissues as validated by immunohistochemistry and was associated with lymph node metastasis. PBK and CCNB1 expression showed a significant positive correlation in TCGA ovarian cancer datasets. Knockdown of PBK inhibited CCNB1 expression in ovarian cancer cells.

Conclusions: PBK promotes ovarian cancer cell proliferation and invasion. PBK knockdown leads to CCNB1 downregulation. These findings suggest that CCNB1 contributes to PBK-mediated oncogenic effects and identify the PBK-CCNB1 axis as a potential therapeutic target for ovarian cancer treatment.

pdz结合激酶通过调控CCNB1促进卵巢癌细胞增殖和侵袭。
背景:卵巢癌是最致命的妇科恶性肿瘤之一,具有诊断晚、复发频繁、死亡率高的特点。pdz结合激酶(PBK)是丝裂原活化蛋白激酶(MAPKK)家族的丝氨酸/苏氨酸激酶,与多种癌症的肿瘤发生有关,但其在卵巢癌中的作用尚未完全确定。本研究旨在探讨PBK对卵巢癌细胞增殖和侵袭的影响。方法:采用基因表达谱交互分析2 (GEPIA2)、临床蛋白质组学肿瘤分析联盟(CPTAC)、Kaplan-Meier Plotter等在线数据库分析PBK和细胞周期蛋白B1 (CCNB1)在正常卵巢组织和卵巢癌组织中的表达。收集临床组织标本,免疫组化检测PBK和CCNB1的表达。采用实时定量聚合酶链反应(PCR)检测临床标本和细胞系中PBK信使RNA (mRNA)的表达水平。Western blot法检测PBK蛋白在卵巢癌细胞系中的表达。选择PBK表达较高的ES2和A2780细胞,利用慢病毒干扰载体构建PBK敲低细胞系。通过细胞计数试剂盒-8 (CCK-8)法、集落形成法和5-乙基-2′-脱氧尿苷(EdU)法探讨PBK敲低对细胞增殖的影响。Transwell法观察其对细胞侵袭的影响。利用癌症基因组图谱(TCGA)和京都基因与基因组百科全书(KEGG)数据库分析PBK相关通路,并预测CCNB1是与PBK最密切相关的基因。结果:与正常对照相比,PBK在卵巢癌组织和细胞系中显著过表达,PBK高表达与较差的总生存期(OS)和无进展生存期(PFS)相关。抑制PBK表达抑制卵巢癌细胞的增殖、集落形成和侵袭。生物信息学分析显示,CCNB1在卵巢癌中显著过表达,CCNB1高表达与不良OS相关。免疫组织化学证实,CCNB1在卵巢癌组织中也显著高表达,并与淋巴结转移有关。PBK与CCNB1表达在TCGA卵巢癌数据集中呈显著正相关。下调PBK可抑制卵巢癌细胞中CCNB1的表达。结论:PBK促进卵巢癌细胞增殖和侵袭。PBK敲低导致CCNB1下调。这些发现表明,CCNB1参与pbk介导的致癌作用,并将PBK-CCNB1轴确定为卵巢癌治疗的潜在治疗靶点。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.10
自引率
0.00%
发文量
252
期刊介绍: Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书